BUSINESS● LOWSep 10 · Sep 10, 2026, 3:49 PM
Revolution a new overweight at Morgan Stanley on RAS-targeted oncology franchise
Seeking Alpha Tech · global
Morgan Stanley has given a new 'overweight' rating to Revolution based on its RAS-targeted oncology franchise. This indicates a positive outlook from the financial firm on the company's performance in cancer treatment development.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS17m agoFinancial sector rise in October: AI shift lifts CBOE, crypto rout hits COINSeeking Alpha TechBUSINESS22m agoCompetition is measured on the billLa Silla Vacía